Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone857-259-3860
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$380,000.00
Profitability
Miscellaneous
Employees65
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions
What is Scholar Rock's stock symbol?
Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."
How were Scholar Rock's earnings last quarter?
Scholar Rock Holding Corp (NASDAQ:SRRK) posted its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.08. The company earned $3.11 million during the quarter, compared to analyst estimates of $5.05 million. View Scholar Rock's Earnings History.
When is Scholar Rock's next earnings date?
What price target have analysts set for SRRK?
2 Wall Street analysts have issued 1-year target prices for Scholar Rock's shares. Their forecasts range from $27.00 to $27.00. On average, they expect Scholar Rock's share price to reach $27.00 in the next twelve months. This suggests a possible upside of 97.1% from the stock's current price. View Analyst Price Targets for Scholar Rock.
What is the consensus analysts' recommendation for Scholar Rock?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scholar Rock.
Has Scholar Rock been receiving favorable news coverage?
News articles about SRRK stock have been trending somewhat positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Scholar Rock earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Scholar Rock.
Are investors shorting Scholar Rock?
Scholar Rock saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 1,649,200 shares, an increase of 10.0% from the April 30th total of 1,499,800 shares. Based on an average daily volume of 110,000 shares, the short-interest ratio is presently 15.0 days. Approximately 11.4% of the shares of the company are short sold. View Scholar Rock's Current Options Chain.
Who are some of Scholar Rock's key competitors?
Some companies that are related to Scholar Rock include Sangamo Therapeutics (SGMO), Alector (ALEC), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Editas Medicine (EDIT), Aerie Pharmaceuticals (AERI), NanoString Technologies (NSTG), Cortexyme (CRTX), Adverum Biotechnologies (ADVM), Momenta Pharmaceuticals (MNTA), Twist Bioscience (TWST), MeiraGTx (MGTX), Voyager Therapeutics (VYGR) and BAVARIAN NORDIC/S (BVNRY).
What other stocks do shareholders of Scholar Rock own?
Who are Scholar Rock's key executives?
Scholar Rock's management team includes the folowing people:
- Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 54)
- Mr. Yung H. Chyung, Chief Medical Officer (Age 43)
- Ms. Rhonda M. Chicko, Chief Financial Officer (Age 53)
- Mr. Alan J. Buckler, Chief Scientific Officer (Age 59)
- Ms. Catherine Hu, Exec. Director of Investor Relations & Corp. Communications
When did Scholar Rock IPO?
(SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of Scholar Rock?
Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scholar Rock's stock price today?
One share of SRRK stock can currently be purchased for approximately $13.70.
How big of a company is Scholar Rock?
Scholar Rock has a market capitalization of $359.30 million and generates $380,000.00 in revenue each year. The company earns $-49,330,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Scholar Rock employs 65 workers across the globe.View Additional Information About Scholar Rock.
What is Scholar Rock's official website?
How can I contact Scholar Rock?
Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]
MarketBeat Community Rating for Scholar Rock (NASDAQ SRRK)
MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote "Outperform" if you believe SRRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
